Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron PharmafiledCriticalRegeneron Pharma
Priority claimed from PCT/US2019/062370external-prioritypatent/WO2020106814A1/en
Publication of MA52675A1publicationCriticalpatent/MA52675A1/en
Publication of MA52675B1publicationCriticalpatent/MA52675B1/en
Medicines That Contain Protein Lipid Enzymes And Other Medicines
(AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents
(AREA)
Abstract
L'invention concerne des anticorps spécifiques ou des fragments de liaison à l'antigène qui se lient à des antigènes staphylococciques, les anticorps et les fragments de liaison à l'antigène présentant une liaison fc atténuée à la protéine a ou à une protéine homologue. L'invention concerne également des compositions comprenant les anticorps et des procédés d'utilisation. Les anticorps et les compositions sont utiles pour traiter une infection staphylococcique, réduire des titres bactériens sériques ou rénaux, et traiter des symptômes associés à une infection staphylococcique. Les anticorps peuvent également prévenir la gravité et/ou la durée de la maladie primaire.The invention relates to specific antibodies or antigen-binding fragments which bind to staphylococcal antigens, wherein the antibodies and antigen-binding fragments exhibit attenuated fc binding to protein a or a homologous protein. The invention also relates to compositions comprising the antibodies and methods of use. The antibodies and compositions are useful for treating staphylococcal infection, reducing serum or renal bacterial titers, and treating symptoms associated with staphylococcal infection. Antibodies can also prevent the severity and/or duration of primary disease.
MA52675A2018-11-212019-11-20
ANTI-STAPHYLOCOCCUS ANTIBODIES AND THEIR USES
MA52675B1
(en)
Clfa protein monoclonal antibody, isolated antiserum, isolated antibody and humanized antibody containing said antibody, diagnostic kit comprising said antibody, method for diagnosing an infection with s.aureus, pharmaceutical composition for treating or preventing said infection , method for inducing an immune response, method for identifying monoclonal antibodies to clfa protein and active fragment isolated from s.aureus clfa protein a